Praxis Precision Medicines, Inc. agreed to acquire Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q) for $1 million on January 18, 2018. As of January 18, 2018, United State Bankruptcy Court, District of Massachusetts, approved the transaction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
54.8 USD | +3.63% | +16.87% | +145.96% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+145.96% | 938M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- PRAX Stock
- News Praxis Precision Medicines, Inc.
- Praxis Precision Medicines, Inc. agreed to acquire Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK: EPRS.Q) for $1 million.